MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

Recent clinical and epidemiological work has raised interest in MDMA and classic psychedelics as potential treatments for psychiatric disorders that elevate risk for suicidal thoughts and behaviours (STBs). Trials since 2011 have reported promising effects of MDMA for treatment‑resistant post‑traumatic stress disorder and social anxiety, and small trials of psilocybin and LSD in people with life‑threatening illness have shown sustained reductions in anxiety and depression. Classic psychedelics have also shown efficacy for some substance use disorders, suggesting multiple pathways through which these compounds might reduce suicide risk. Jones and colleagues frame the present study as an attempt to extend prior population‑level analyses by examining non‑causal associations between lifetime use of MDMA/ecstasy and classic psychedelics and measures of recent psychological distress and STBs. Using more recent National Survey on Drug Use and Health (NSDUH) data than some earlier studies, the investigators test whether self‑reported lifetime use of MDMA/ecstasy or specific classic psychedelics (notably psilocybin) is associated with lower odds of past month serious psychological distress and past year suicidal ideation, planning, and attempts.

The study analysed pooled cross‑sectional data from twelve years of the National Survey on Drug Use and Health (NSDUH), covering 2008–2019. NSDUH uses a complex, multistage probability design and computer‑assisted self‑interviewing to sample US residents aged 12 and older; the analytic sample across those years comprised 484,732 respondents. Lifetime self‑reported use of a set of substances served as the main independent variables, including MDMA/ecstasy, classic psychedelics (psilocybin, LSD, peyote, mescaline), other illegal drugs (cocaine, heroin, PCP), and commonly misused legal substances (inhalants, prescription pain relievers, tranquilizers, stimulants, sedatives, and marijuana). Four binary outcome variables from NSDUH were examined: past month serious psychological distress (a composite of six symptom domains scored 0–4 and coded positive for a total score of 13 or greater), past year suicidal ideation, past year suicidal planning, and past year suicide attempt. The investigators fit four multivariable logistic regression models, one for each outcome, to estimate non‑causal associations between lifetime substance use and the outcomes. Models adjusted for a comprehensive set of covariates: sex, age, race/ethnicity (detailed categories), educational attainment (multiple levels), self‑reported engagement in risky behaviour, annual household income (four bands), marital status, and survey year. Analyses were conducted in R (version 3.5.3) using the Survey package and applied NSDUH sampling weights and its complex design features. The text indicates the analytic approach followed prior large‑survey work in this area; the investigators did not report use of longitudinal or causal inference techniques beyond covariate adjustment.

Overall prevalence estimates in the pooled sample were: past month serious psychological distress 5.3%, past year suicidal ideation 4.1%, past year suicidal planning 1.2%, and past year suicide attempt 0.5%. Lifetime psilocybin use was reported by 9.4% of respondents and lifetime MDMA/ecstasy use by 7.1%. Demographic patterns differed modestly by substance. Lifetime MDMA/ecstasy users were disproportionately male, Non‑Hispanic White, higher income (≥$75,000), more likely to have at least a high school diploma or college education, and reported seldom engagement in risky behaviours; lifetime psilocybin users showed a broadly similar profile but skewed slightly older. In adjusted logistic regression models, lifetime MDMA/ecstasy use was associated with reduced odds of past year suicidal ideation (10% lower odds; OR = 0.90; 95% CI = 0.84–0.97; p < 0.01) and with reduced odds of past year suicidal planning (12% lower odds; OR = 0.88; 95% CI = 0.78–0.99; p < 0.05). Lifetime psilocybin use was associated with reduced odds of past month serious psychological distress (22% lower odds; OR = 0.78; 95% CI = 0.73–0.84; p < 0.001) and reduced odds of past year suicidal ideation (10% lower odds; OR = 0.90; 95% CI = 0.83–0.96; p < 0.01). Associations between psilocybin use and past year suicidal planning (OR = 0.88; 95% CI = 0.76–1.01; p = 0.08) and past year suicide attempt (OR = 0.85; 95% CI = 0.72–1.01; p = 0.07) were described as marginal. By contrast, lifetime use of other classic psychedelics (LSD, peyote, mescaline) generally showed no protective associations; LSD was associated with a small increased odds of past year suicidal ideation (7% higher odds; OR = 1.07; 95% CI = 1.00–1.15; p < 0.05). Use of other illegal and commonly misused substances either had no association with the outcomes or was associated with increased odds of psychological distress and STBs.

Jones and colleagues interpret the principal findings as evidence of non‑causal associations between lifetime MDMA/ecstasy and psilocybin use and lower odds of recent psychological distress and some measures of suicide risk in the US adult population. Specifically, lifetime MDMA/ecstasy use related to reduced odds of past year suicidal thinking and planning, while lifetime psilocybin use related to reduced odds of past month psychological distress and past year suicidal ideation, with marginal associations for planning and attempts. The investigators situate these results within prior clinical and epidemiological research, noting consistency with trials and earlier survey studies that suggest therapeutic effects of MDMA and psilocybin for conditions linked to suicide risk. They apply Hill’s criteria as a heuristic: the study provides some elements such as strength, consistency, specificity, plausibility, and coherence, but lacks experimental evidence and a demonstrated dose–response relationship; randomized controlled trials are therefore highlighted as the next step to address causality. Potential biological mechanisms advanced by the authors include serotonergic release and reuptake inhibition, increased neuroplasticity via brain‑derived neurotrophic factor (BDNF) for MDMA, and oxytocin‑mediated increases in social connectedness and reductions in amygdala fear responses. For psilocybin, suggested mechanisms include modulation of glutamatergic transmission, downregulation of 5‑HT2A receptors, and reductions in inflammatory markers linked to STBs. The authors caution that pharmacological interpretation is limited in naturalistic survey data because MDMA/ecstasy may be adulterated in community settings; nevertheless, they note that finding protective associations despite potential impurity may be notable. Policy and safety implications are also discussed. The paper notes that MDMA and classic psychedelics retain Schedule 1 status, which constrains research, and argues for reconsideration of that designation to facilitate clinical trials. The authors point out that monitored clinical research of MDMA in recent years has not reported major adverse events, but they also acknowledge documented short‑term risks: therapeutic sessions can yield intense emotional reactions and transient symptom increases, and recreational use is sometimes accompanied by paranoia, panic, or thoughts of death in roughly one quarter of users in some samples. These considerations motivate calls for controlled trials and further safety research. Key limitations acknowledged by the investigators are emphasised: the cross‑sectional and observational design precludes causal inference; lifetime measures of substance use do not establish temporal precedence relative to past month/year outcomes; unmeasured pre‑existing differences (for example personality traits) between users and non‑users could confound associations; the analyses did not assess mediators or moderators of effect; and the impurity of street MDMA/ecstasy limits pharmacological conclusions. The authors recommend randomized controlled and longitudinal studies to address these limitations and to clarify mechanisms.

The study concludes that lifetime MDMA/ecstasy and psilocybin use are associated with lower odds of psychological distress and some measures of suicide risk in a large, representative sample of US adults. While emphasising the observational, non‑causal nature of the findings, Jones and colleagues argue that the results add to evidence supporting further clinical trials and research into the therapeutic potential, mechanisms, and safety of MDMA and psilocybin.